References
1. Jiang Y, Zhang J, Guo D, et al. Entire ABL1 Gene Deletion Without BCR/ABL1 Rearrangement in a Female Patient with B-Cell Precursor Acute Lymphoblastic Leukemia. Onco Targets Ther 2020;13 :783-90 doi: 10.2147/ott.S238336[published Online First: Epub Date]|.
2. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leukemia & lymphoma 2019;60 (11):2606-21 doi: 10.1080/10428194.2019.1605071[published Online First: Epub Date]|.
3. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nature reviews. Cancer 2008;8 (4):288-98 doi: 10.1038/nrc2349[published Online First: Epub Date]|.
4. Sender L, Zabokrtsky KB. Adolescent and young adult patients with cancer: a milieu of unique features. Nature reviews. Clinical oncology 2015;12 (8):465-80 doi: 10.1038/nrclinonc.2015.92[published Online First: Epub Date]|.
5. Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA: a cancer journal for clinicians 2020;70 (6):443-59 doi: 10.3322/caac.21637[published Online First: Epub Date]|.
6. Friend BD, Schiller GJ. Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults. Blood reviews 2018;32 (2):122-29 doi: 10.1016/j.blre.2017.09.005[published Online First: Epub Date]|.
7. Anderson C, Lund JL, Weaver MA, Wood WA, Olshan AF, Nichols HB. Noncancer mortality among adolescents and young adults with cancer. Cancer 2019;125 (12):2107-14 doi: 10.1002/cncr.32063[published Online First: Epub Date]|.
8. Katsibardi K, Papadakis V, Charisiadou A, Pangalis A, Polychronopoulou S. Blood stream infections throught the entire course of acute lymphoblastic leukemia treatment. Neoplasma 2011;58 (4):326-30 doi: 10.4149/neo_2011_04_326[published Online First: Epub Date]|.
9. Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. American journal of hematology 2018;93 (7):913-20 doi: 10.1002/ajh.25124[published Online First: Epub Date]|.
10. Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2015;21 (4):337-43 doi: 10.1016/j.cmi.2014.11.022[published Online First: Epub Date]|.
11. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. The Journal of infection 2014;68 (4):321-31 doi: 10.1016/j.jinf.2013.12.006[published Online First: Epub Date]|.
12. Inaba H, Pei D, Wolf J, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Annals of oncology : official journal of the European Society for Medical Oncology 2017;28 (2):386-92 doi: 10.1093/annonc/mdw557[published Online First: Epub Date]|.
13. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28 (32):4790-9 doi: 10.1200/jco.2010.28.3473[published Online First: Epub Date]|.
14. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia & lymphoma 2011;52 (12):2237-53 doi: 10.3109/10428194.2011.596963[published Online First: Epub Date]|.
15. Husson O, Huijgens PC, van der Graaf WTA. Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies. Blood 2018;132 (4):385-92 doi: 10.1182/blood-2017-11-778555[published Online First: Epub Date]|.
16. Pritchard MT, Butow PN, Stevens MM, Duley JA. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. Journal of pediatric hematology/oncology 2006;28 (12):816-23 doi: 10.1097/01.mph.0000243666.79303.45[published Online First: Epub Date]|.
17. Tebbi CK, Cummings KM, Zevon MA, Smith L, Richards M, Mallon J. Compliance of pediatric and adolescent cancer patients. Cancer 1986;58 (5):1179-84 doi: 10.1002/1097-0142(19860901)58:5<1179::aid-cncr2820580534>3.0.co;2-e[published Online First: Epub Date]|.
18. Liang T, Xu C, Cheng Q, Tang Y, Zeng H, Li X. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Hematologic Malignancy: A Retrospective Study from Central South China. Microbial drug resistance (Larchmont, N.Y.) 2021;27 (6):800-08 doi: 10.1089/mdr.2020.0033[published Online First: Epub Date]|.
19. Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. The Journal of antimicrobial chemotherapy 2010;65 (2):333-41 doi: 10.1093/jac/dkp411[published Online First: Epub Date]|.
20. Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Annals of hematology 2013;92 (4):533-41 doi: 10.1007/s00277-012-1631-y[published Online First: Epub Date]|.
21. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. The Journal of infection 2009;58 (4):299-307 doi: 10.1016/j.jinf.2009.02.002[published Online First: Epub Date]|.
22. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. The Journal of hospital infection 2008;68 (2):108-15 doi: 10.1016/j.jhin.2007.10.011[published Online First: Epub Date]|.
23. Jarløv JO, Højbjerg T, Busch-Sørensen C, et al. Coagulase-negative Staphylococci in Danish blood cultures: species distribution and antibiotic susceptibility. The Journal of hospital infection 1996;32 (3):217-27 doi: 10.1016/s0195-6701(96)90148-6[published Online First: Epub Date]|.
24. Zhu GQ, Xu CH, Lin QS, et al. [Analysis of pathogens and clinical characteristics of bloodstream infection in neutropenic children with hematological malignancies from 2014 to 2018]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020;41 (8):655-60 doi: 10.3760/cma.j.issn.0253-2727.2020.08.007[published Online First: Epub Date]|.
25. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23 (31):7958-66 doi: 10.1200/jco.2005.01.6378[published Online First: Epub Date]|.
26. Kameda K, Kimura SI, Akahoshi Y, et al. High Incidence of Afebrile Bloodstream Infection Detected by Surveillance Blood Culture in Patients on Corticosteroid Therapy after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016;22 (2):371-77 doi: 10.1016/j.bbmt.2015.09.019[published Online First: Epub Date]|.
27. van Walraven C, Wong J. Independent influence of negative blood cultures and bloodstream infections on in-hospital mortality. BMC infectious diseases 2014;14 :36 doi: 10.1186/1471-2334-14-36[published Online First: Epub Date]|.
28. Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I. Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients. BMC infectious diseases 2010;10 :135 doi: 10.1186/1471-2334-10-135[published Online First: Epub Date]|.
29. [Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020)]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020;41 (12):969-78 doi: 10.3760/cma.j.issn.0253-2727.2020.12.001[published Online First: Epub Date]|.
30. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2012;18 (3):268-81 doi: 10.1111/j.1469-0691.2011.03570.x[published Online First: Epub Date]|.
31. Tang Y, Wu X, Cheng Q, Li X. Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections. Infection 2020;48 (1):109-16 doi: 10.1007/s15010-019-01370-x[published Online First: Epub Date]|.
32. Tang Y, Cheng Q, Yang Q, et al. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections. Infection 2018;46 (4):513-21 doi: 10.1007/s15010-018-1151-3[published Online First: Epub Date]|.
33. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Critical care (London, England) 2014;18 (6):596 doi: 10.1186/s13054-014-0596-8[published Online First: Epub Date]|.